Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
May 04, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results

- Company records $59.4 million in total net product sales - - JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
February 28, 2015 07:15 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Rare Disease Day

CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
February 26, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results

- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
February 25, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference

CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
April 09, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
February 10, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
January 20, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
March 06, 2013 07:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results

CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
January 06, 2012 12:57 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results

Efficacy and Safety Profile Maintained Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...